Logo image of ALTS

ALT5 SIGMA CORP (ALTS) Stock Fundamental Analysis

NASDAQ:ALTS - Nasdaq - US47089W1045 - Common Stock - Currency: USD

6.035  -0.95 (-13.54%)

Fundamental Rating

2

Overall ALTS gets a fundamental rating of 2 out of 10. We evaluated ALTS against 194 industry peers in the Pharmaceuticals industry. ALTS has a bad profitability rating. Also its financial health evaluation is rather negative. ALTS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ALTS has reported negative net income.
In the past year ALTS had a positive cash flow from operations.
In the past 5 years ALTS reported 4 times negative net income.
In multiple years ALTS reported negative operating cash flow during the last 5 years.
ALTS Yearly Net Income VS EBIT VS OCF VS FCFALTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

1.2 Ratios

With a decent Return On Assets value of -8.92%, ALTS is doing good in the industry, outperforming 70.62% of the companies in the same industry.
The Return On Equity of ALTS (-27.10%) is better than 65.98% of its industry peers.
Industry RankSector Rank
ROA -8.92%
ROE -27.1%
ROIC N/A
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTS Yearly ROA, ROE, ROICALTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

ALTS has a better Gross Margin (49.24%) than 62.89% of its industry peers.
In the last couple of years the Gross Margin of ALTS has grown nicely.
ALTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
ALTS Yearly Profit, Operating, Gross MarginsALTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

1

2. Health

2.1 Basic Checks

ALTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALTS has been increased compared to 1 year ago.
The number of shares outstanding for ALTS has been increased compared to 5 years ago.
Compared to 1 year ago, ALTS has a worse debt to assets ratio.
ALTS Yearly Shares OutstandingALTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALTS Yearly Total Debt VS Total AssetsALTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ALTS has an Altman-Z score of 0.12. This is a bad value and indicates that ALTS is not financially healthy and even has some risk of bankruptcy.
ALTS has a Altman-Z score (0.12) which is comparable to the rest of the industry.
ALTS has a debt to FCF ratio of 18.18. This is a negative value and a sign of low solvency as ALTS would need 18.18 years to pay back of all of its debts.
ALTS has a better Debt to FCF ratio (18.18) than 78.35% of its industry peers.
ALTS has a Debt/Equity ratio of 0.55. This is a neutral value indicating ALTS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.55, ALTS is doing worse than 61.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 18.18
Altman-Z 0.12
ROIC/WACCN/A
WACC10.09%
ALTS Yearly LT Debt VS Equity VS FCFALTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

ALTS has a Current Ratio of 0.83. This is a bad value and indicates that ALTS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ALTS (0.83) is worse than 87.63% of its industry peers.
A Quick Ratio of 0.83 indicates that ALTS may have some problems paying its short term obligations.
ALTS has a worse Quick ratio (0.83) than 81.96% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.83
ALTS Yearly Current Assets VS Current LiabilitesALTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

ALTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.79%, which is quite impressive.
Measured over the past years, ALTS shows a very negative growth in Revenue. The Revenue has been decreasing by -18.62% on average per year.
EPS 1Y (TTM)88.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.87%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%N/A

3.2 Future

ALTS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.61% yearly.
Based on estimates for the next years, ALTS will show a very strong growth in Revenue. The Revenue will grow by 65.13% on average per year.
EPS Next Y7.14%
EPS Next 2Y32.1%
EPS Next 3Y28.61%
EPS Next 5YN/A
Revenue Next Year185.91%
Revenue Next 2Y117.15%
Revenue Next 3Y79.76%
Revenue Next 5Y65.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALTS Yearly Revenue VS EstimatesALTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
ALTS Yearly EPS VS EstimatesALTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ALTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTS Price Earnings VS Forward Price EarningsALTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALTS indicates a somewhat cheap valuation: ALTS is cheaper than 77.32% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 135.36
EV/EBITDA N/A
ALTS Per share dataALTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

ALTS's earnings are expected to grow with 28.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.1%
EPS Next 3Y28.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALT5 SIGMA CORP

NASDAQ:ALTS (7/29/2025, 5:52:32 PM)

6.035

-0.95 (-13.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01
Earnings (Next)08-18 2025-08-18
Inst Owners7.89%
Inst Owner Change0%
Ins Owners4.19%
Ins Owner Change0%
Market Cap105.31M
Analysts82.86
Price Target24.48 (305.63%)
Short Float %6.58%
Short Ratio3.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.84
P/FCF 135.36
P/OCF 135.36
P/B 4.1
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)0.04
FCFY0.74%
OCF(TTM)0.04
OCFY0.74%
SpS1.03
BVpS1.47
TBVpS-1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.92%
ROE -27.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.24%
FCFM 4.31%
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 18.18
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.83
Altman-Z 0.12
F-Score5
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.87%
EPS Next Y7.14%
EPS Next 2Y32.1%
EPS Next 3Y28.61%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%N/A
Revenue Next Year185.91%
Revenue Next 2Y117.15%
Revenue Next 3Y79.76%
Revenue Next 5Y65.13%
EBIT growth 1Y-45.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.41%
EBIT Next 3Y44.5%
EBIT Next 5Y44.66%
FCF growth 1Y119.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.92%
OCF growth 3YN/A
OCF growth 5YN/A